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Multiple technologies have emerged for structural diversiﬁcation and efﬁcient production of metabolites
of drug molecules. These include expanded use of enzymatic and bioorganic transformations that mimic
biological systems, biomimetic catalysis and electrochemical techniques. As this ﬁeld continues to
mature the breadth of transformations is growing beyond simple oxidative processes due in part to par-
allel development of more efﬁcient catalytic methods for functionalization of unactivated scaffolds. These
technologies allow for efﬁcient structural diversiﬁcation of both aromatic and aliphatic substrates in
many cases via single step reactions without the use of protecting groups.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.The generation of metabolites of active drug molecules is an diversiﬁcation.4 The purpose of this review is to highlight technol-
important part of drug discovery as we attempt to understand
the fate of pharmaceutical agents in the body. Typically, a circulat-
ing metabolite is sought out and isolated from an in vivo study as
the result of poor PK or unexpected pharmacology. Confounding
this analysis can be the transient or reactive nature of somemetab-
olites.1 Subsequent to tedious mass spectral analysis, a structure is
proposed and a ﬁrst attempt to prepare sufﬁcient material might
be carried out using liver slices or microsomes, for example.2 When
larger quantities are required, the task of producing a particular
metabolite is assigned to the medicinal chemist via a dedicated
synthetic route that may or may not intersect common building
blocks. In addition this process occasionally requires redesign
when the proposed molecule fails to match the isolated metabolite.
Out of this need, various more efﬁcient biomimetic technologies
have been developed to aid medicinal chemistry teams in the pro-
duction and study of metabolites.2,3 The ﬁeld of biomimetic chem-
istry has grown beyond simple oxidative transformations and now
includes many other related disciplines that allow for structuralogies related to structural diversiﬁcation and generation of metab-
olites including enzymatic, catalytic and electrochemical methods.
Together, these and other technologies are making single point
structural modiﬁcations more efﬁcient.5
The desire to selectively functionalize lead molecules is not
new. For example, during the golden age of steroid research, teams
utilized enzymatic transformations to create a diversity of biolog-
ically active steroids from plant based starting materials.6 In the
decades since, the understanding of the mechanisms underlying
biological oxidation processes has increased7 and research teams
have been inspired to prepare novel metalloporphyrin catalysts
that mimic these reactions. Research in this area continues to ex-
pand beyond metabolite production into the novel functionaliza-
tion of common building blocks. However as Groves, et al. have
pointed out, even with the recent advances in bioinorganic chem-
istry, the structure and reactivity of all of the metalloenzymes is
not fully understood.8 With the recent growth in the use of electro-
chemistry, the collection of efﬁcient technologies available for
structural diversiﬁcation is beginning to grow. The ability to
manipulate unfunctionalized molecules in ways that were previ-
ously inaccessible via traditional methods is particularly relevant
5472 K. P. Cusack et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5471–5483to drug discovery for example.9,10 Structural diversiﬁcation allows
the designer to navigate through safety and toxicity challenges
while the ability to selectively oxidize molecules can be advanta-
geous to physicochemical properties via lowering of the logP.
Biocatalysis: Access to speciﬁc drug metabolites is often key for
the success of drug discovery programs and enzymatic transforma-
tions can contribute to the synthesis of metabolites and pseudome-
tabolites (metabolites not observed in mammals). This section
focuses on oxidative phase I metabolic transformations11 involving
cytochrome P450s (CYPs), ﬂavin-dependent monooxygenases
(FMOs), monoamineoxidases (MAOs) and dehydrogenases.12 Phase
II transformations, while important, are beyond the scope of this
digest.13 Metabolic phase I transformations include a wide variety
of reactions like dealkylations, epoxidations and isomerizations,
but site-selective hydroxylations by direct C–H functionalization
are among the most intriguing (Scheme 1).14 The vast majority of
hydroxylations in mammalian metabolism of xenobiotics results
from the action of cytochrome P450s, in particular CYP1A2, 2B6,
2C9, 2C19, 2D6, 2E1 and 3A4.15
Besides microsomal preparations, pure recombinant CYP (rCYP)
and FMO lyophilisates are standard tools with high value in metab-
olism-related R&D assays. However, compared to the use of recom-
binant enzymes, the expression of a certain enzyme in a bacterial
host represents a modiﬁcation of this technique being suitable
for small scale preparative metabolite generation. Furthermore,
the high potential of microorganisms in whole cells has been used
for the creation of molecular diversity far beyond the observed
mammalian metabolic transformations. One example being the
construction of a CYP expression library based on Escherichia coli
expression for P450 monooxygenases, which after careful screen-
ing and optimization revealed a rapid biotransformation-system
on multi-well plates (Fig. 1).16NH
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Scheme 1. Diversity of enzymatic hydroxylation sitesMicrobial cultures provide higher enzyme activities, long-term
stability and easier scale-up to prepare puriﬁed metabolites. These
parameters support the use of whole cell enzymatic preparations
as they have proven to be more efﬁcient in terms of scalability of
metabolite production, enzyme activity and costs. In addition, no
regeneration system is required when using whole cell systems,
offering another advantage.17 Current practices within the phar-
maceutical industry are trending towards the establishment of
in-house screening technologies of representative diversity using
both microbial biocatalysts as well as microsomal preparations
and recombinant systems and the types of biocatalyst applications
are summarized in Table 1.18
The direct correlation of bacterial or fungal P450s with speciﬁc
human CYP isoforms or certain mammalian metabolite patterns
still represents a future challenge but would tremendously facili-
tate strain selection. Remarkable progress has been made to opti-
mize the correlation of microbial and mammalian oxidative drug
metabolism during the last years by directed biocatalyst engineer-
ing.19 Within the area of bacterial mutants, BM-3 variants of P450
derived from Bacillus megaterium (CYP 102A1) are of particular
interest, as they accept a broader substrate range and offer greater
potential for use at larger scale than human CYPs.20 In this context,
a drug library screening for metabolic activity towards a structur-
ally diverse set of 43 drug-like compounds has been reported using
BM3 mutants in cytosolic fractions.21,22
The application and combination of different methods such as
human liver (HLM) and renal (HRM) microsomes, recombinant
P450s and FMOs is illustrated by a recent report of Usmani et al.
(Scheme 2).23 The enzymes involved in the primary metabolism
of Lorcaserin, a 5-HT2C agonist, are described along with CYP inhi-
bition experiments revealing the contribution of CYPs to the met-
abolic pathway.O
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Figure 1. Preparation and use of a bacterial CYP reaction array. M9 mix medium: ampicillin medium to support robust and selective growth; Chaperone: protein assisting
non-covalent folding/unfolding; IPTG: isopropyl b-D-1-thiogalactopyranoside; 5-ALA: d-aminolevulinic acid.16
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Scheme 2. Primary in vitro metabolites of lorcaserin produced by rCYPs.65
Table 1
Types of in vitro biocatalyst applications in metabolisma
Application Suitable biocatalyst (enzyme preparation, whole
cell, etc.)
Analytical proﬁling of drug candidates or drugs in identiﬁcation of metabolic pathways or metabolic hot spots Commercial (H)LM preparations
rCYPs (human) as whole cells or microsomes
[rCYPs (mammalian)]
[Microbial biocatalysts,b whole cells]
Small-scale synthesis of human drug metabolites (milligram scale) for structure conﬁrmation (NMR, MS) rCYPs (human) as whole cells or microsomes
[Microbial biocatalysts, whole cells]
Preparative scale synthesis of major human drug metabolites for PK and tox studies (10–100 mg) or derivatization
(100 mg—multi-gram)
rCYPs (human) as whole cells or microsomes
Microbial biocatalysts,b whole cells
Lead diversiﬁcation: Identiﬁcation and production of compounds with modiﬁed properties (100 mg—multi-gram) Microbial biocatalysts,b whole cells
a Preferred methods given without brackets.18
b With known biocatalytic similarity to mammalian/human CYPs.
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of the anti-depressant NVP-AAG561 by rCYP3A4 co-expressed in
E. coli exempliﬁes the interface between recombinant systems
and microbial transformations (Scheme 3).18
Aromatic versus aliphatic site-selectivity is attainable as in the
case of the anti-cancer drug Dasatinib24 while regiocontrol of aro-
matic hydroxylation is illustrated in the oxidation of Fluvastatin.Two very similar phenolic metabolites could successfully be syn-
thesized with either shake-ﬂask cultures or disposable bioreactor
bags (Scheme 4).25 Other examples include the synthesis of 100
mg quantities of the major active metabolites of Carbamazepine
(Scheme 5).26
In addition, several contract research companies emerged over
the last several years, offering screening and scale-up on a fee for
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Scheme 3. Preparation of NVP-AAG561 metabolites with rCYP3A4 co-expressed in Escherichia coli.18
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tion conditions using organometallic catalysts in a multi-well par-
allel format mimicking a synthetic liver28 and CYP screening
plates,27 which have emerged as modern processes using different
CYP, microbial or even fungal systems.
High lipophilicity of drug candidates leading to promiscuity,
poor ADME and PK properties29 is still one of the major challenges
in drug discovery. Late-stage modiﬁcation of active compounds
and advanced intermediates has become an attractive approach
to address these issues. Replacement of a hydrogen atom by a hy-
droxyl group signiﬁcantly lowers lipophilicity and often leads to
increased metabolic stability (Scheme 6).30
Enzymes with their high chemoselectivity and unique ability
for direct C–H activation seem to be well suited for this type of
late-stage aliphatic or aromatic oxidation in the presence of several
other functional groups.
The lead optimization process is often inﬂuenced by results
from metabolic studies driving attempts to either block metabolic
hot spots or follow up on active metabolites with enhanced micro-
somal stability and improved pharmacokinetic properties. A classic
example is the discovery of the cholesterol lowering agent Ezetim-
ibe. In vivo studies of azetidinone derivatives like ()-SCH 48461
led to reduction of serum cholesterol although the parent com-
pound had hardly any acyl coenzyme A cholesterol acyltransferase
inhibitory activity. Bioproﬁling of the numerous metabolites of
()-SCH 48461 revealed an active phenol metabolite. Subsequent
optimization and blocking of a metabolic hot spot by ﬂuorine even-
tually yielded Ezetimibe (Fig. 2).
A related approach describes the combination microbial and
chemical methods for the late-stage ﬂuorination of drug candi-
dates to enhance microsomal stability.31
Complementary to developing screening sets of cytochrome
P450 enzymes with activity for a wide variety of drug-like com-
pounds, in silico drug metabolism tools have the potential to sup-
port the selection of cytochrome P450 subtypes for selective
oxidation of drug candidates.32 Cytochrome P450 mediated oxida-
tions have impacted the design of prodrugs for a long time, for
example, Tegafur is a prodrug for the thymidylate synthase inhib-
iting anticancer drug 5-ﬂuorouracil that is not as rapidly degraded
and is less toxic than the drug itself (Scheme 7). Future develop-
ments may include prodrugs targeting individual P450 enzymes
to achieve organ and/or compartment speciﬁc release of the active
drug. Particularly in cancer treatment more cytotoxic drugs could
be delivered as prodrugs site-selectively to avoid systemic toxicity.
Though not prohibitive common cytochrome P450-related prob-
lems like slow conversion of a prodrug and hence slow drug re-
lease, inter-patient variation and potential drug–drug
interactions need to be considered.33
In the ﬁeld of metabolite generation the traditional static
enzymatic incubation more recently has been complemented by
an advantageous ﬂow-based approach: developments contain
microﬂuidic hepatic co-culture platforms to enhance metabolite
production and help to improve IVIV correlations34 as well as
lab-on-a-chip approaches imitating drug metabolism in PEGylat-
ed HLM, coupled with SPE puriﬁcation and MS detection
(Fig. 3).35
One of the latest developments in the use of cytochrome P450
BM3 mutants for structural diversiﬁcation of compounds exploits
the chiral environment of the iron(II)-porphyrin-containing bind-
ing pocket for asymmetric cyclopropanation of oleﬁns with diazo-
acetic acid esters (Scheme 8).36
Wider use of enzymatic transformations for metabolite and/or
pseudometabolite synthesis, as well as combinations of enzymatic
with classic chemical reactions for late-stage derivatization of ad-
vanced intermediates and/or drug-like compounds are likely to
ﬁnd increased use in drug discovery in the future.Biomimetic catalysis: Catalytic reactions continue to be a readily
available source of transformations for bench scientists requiring
little in the way of specialized equipment. New catalytic methods
have been identiﬁed that greatly improve the step- and atom-
economy of synthetic transformations thus transforming histori-
cally laborious processes into routine experiments. For example
biomimetic metalloporphyrin catalysts and C–H activation proto-
cols are now routinely utilized in the preparation of pseudometab-
olites and derivatives of the starting compound.10 In addition,
parallel development of catalysts for the direct ﬂuorination of sub-
strates provides an approach to minimize metabolism of drug mol-
ecules leading to fewer metabolites and potentially safer drugs.37
To date multiple model systems have been developed that mi-
mic the transformations seen in vivo. The greatest value of these
systems is the ability to produce multiple analogs in sufﬁcient
quantity to enable complete chemical characterization and phar-
macological testing.2 Metalloenzymes analogous to the panel of
cytochrome P450 enzymes present in the human liver is commer-
cially available for example.28 The ability to utilize metalloporphy-
rin catalysts in vitro to prepare drug metabolites directly from
parent drug is a signiﬁcant leap forward for medicinal chemistry
teams driving metabolite studies earlier into the drug development
cycle. For example the discovery of both active metabolites of Nel-
ﬁnavir could have been more systematic rather than serendipitous
during human testing (Scheme 9).38
Similar advances in C–H insertion chemistry can be exploited to
transform molecules in a single step via previously inefﬁcient
methods. The direct regioselective functionalization of aromatic
and heteroaromatic compounds is now readily achievable and
the reader is directed towards a recent review from Glorius et al.10
for the scope of reactions in this ﬁeld. Catalytic, nonporphyrin
methods for C–H functionalization often provide an improved syn-
thetic route to metabolites that mimics the selectivity of the
metabolizing enzyme, but with signiﬁcantly reduced reaction
times and higher yields, thus allowing rapid access to key metab-
olites for further investigation and characterization. These meth-
ods provide a complementary approach in that the C–H bond
that is oxidized can vary from the position that is selected by the
enzyme. These alternative products provide novel analogs and
new synthetic handles for further, late-stage compound
functionalization.
M. Christina White and co-workers recently developed an elec-
trophilic iron complex, Fe(PDP), which uses H2O2, an inexpensive,
environmentally friendly oxidant to affect highly selective oxida-
tions of tertiary sp3 C–H bonds.39 The reactions are run at ambient
temperature and the catalyst achieves P450-like selectivity. An
example of this reactivity is the oxidation of (+)-artemisinin (1)
(Scheme 10), where the C-10 position is oxidized in 34% yield,
54% yield after recycling the starting material two times, to give
(+)-10b-hydroxyartemisinin (2). Microbial cultures of Cunningham-
ella echinulata furnish a 47% yield of (+)-10b-hydroxyartemisinin
(2) in 4 days.40 Fe(S,S-PDP) (3) provides the product in higher over-
all yield than microbial cultures, in a shorter time (three 30 min
reactions) and with a 10-fold higher volume throughput (0.033 M
vs. 0.0035 M). A slow addition protocol can also be employed using
the Fe catalyst, which removes the need for recycling starting
materials to provide the product in 51% isolated yield.41
This method has been extended to include secondary aliphatic
C–H bonds,42–44 which are challenging to selectively oxidize due
to their abundance in organic structures and their chemical
inertness. The two-step oxidation of ()-ambroxide (4) to (+)-
2-oxo-sclareolide (11) demonstrates the selectivity of sequential
oxidations with the ﬁrst oxidation occurring at the C–H bond alpha
to the ether to give (+)-(3R)-sclareolide (5) in 80% yield using
15 mol % of catalyst 7 (Scheme 11). The newly installed lactone
now serves as an electron withdrawing group and deactivates
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5476 K. P. Cusack et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5471–5483the B and C rings, resulting in oxidation of the C2 of the A ring to
afford (+)-2-oxo-sclareolide (11) as the major product in 46% iso-
lated yield employing 25 mol % of the Fe(R,R-PDP) catalyst (7).
Microbial enzyme oxidations of ()-ambroxide and (+)-sclareolide
require longer reaction times (3–14 days) and provide a minimal
yield of sclareolide (2%).45,46 The major metabolite formed from
fermentation of ()-ambroxide with Botrytis cinerea is 1b-hydro-
xy-8-epiambrox (6). Importantly, no formation of oxo-sclareolide
11 or 12 was observed when sclareolide was treated with Botrytis
cinerea, demonstrating the complementary nature of these cata-
lysts to enzymatic oxidations.
The C–H functionalizations are guided by electronic, steric, and
stereoelectronic effects. These effects can be overridden by the
presence of a carboxylic acid in the molecule, which serves as a
directing group.48
Costas and co-workers designed an iron-based catalyst with li-
gands similar to the ligand used by the White group but with
pinene fused to the pyridine, with the hypothesis that the structur-
ally elaborate ligand will provide both stability of the catalyst to-
ward degradation pathways, allowing for lower catalyst loadings,
and an increase in selectivity, closely mimicking an enzyme.49
Changes in the regioselectivity of the oxidized products can be dic-
tated by the chirality of the catalyst, the diamine ligand and the
orientation of the pinene. Sclareolide was obtained in 70% yield
utilizing only 3 mol % of catalyst 8 (Scheme 11). Subsequent oxida-
tion of (+)-sclareolide occurs at the C1, C2, and C3 methylenes with
varying selectivity. Changes in the selectivity ratios of the second-
ary C–H bonds that are oxidized, based on the catalyst that is em-
ployed, provide synthetically useful yields of products. Catalyst 13
provides an excellent yield (78%) of a mixture of 10, 11, and 12.
Interestingly, when catalyst 13 is utilized and the reaction temper-
ature is lowered to 35 C, oxidation at C1 yields 10 as the major
product. Other catalysts are not active at this low temperature.
This change in regioselectivity of the methylene oxidation demon-Cl
N
S N
N
O
O
R
R
H
OH
clogD7.4
3.28
1.69
HL
Scheme 6. Hydroxylated aldosterone synthase inhibitor wistrates the orthogonal reactivity of this catalyst to others in the lit-
erature, providing access to different oxidation products.
Aside from iron, other metals have also been explored for C–H
oxidation (Table 2). A recent example is the Cp⁄Ir precatalysts by
Crabtree and coworkers that use NaIO4 as a mild oxidant.50 The
authors demonstrate the late-stage utility of this method by
exploring oxidation of various natural products. No reaction oc-
curred when artemisinin was subjected to 9, which is in contrast
to the iron complex developed by the White group that oxidized
the C-10 methine vide supra. Sclareolide was obtained in 25% yield
when ()-ambroxide was subjected to 10 mol % of precatalyst 9
with oxidation occurring at the activated methylene, alpha to the
oxygen (Scheme 11). Sclareolide oxidation using precatalyst 9
afforded 2-oxo-sclareolide (11) and 3-oxo-sclareolide (12) in 17%
and 5% yield, respectively. Notably, this method and the others dis-
cussed above selectively oxidize unactivated methylene groups
with numerous C–H bonds and a lactone present.
Nonheme catalysts should serve as powerful tools in drug dis-
covery. These catalysts provide synthetically valuable yields of
metabolites with signiﬁcantly reduced reaction times. They also
provide products that are complementary to those formed in enzy-
matic reactions. These alternative products provide both new mol-
ecules for characterization and also a functional group that can be
exploited for further compound diversiﬁcation. While recent
examples for Phase I type oxidation have been discussed, other
late-stage C–H functionalization reactions for compound diversiﬁ-
cation have also been developed.51,52M t1/2 [min]
6
>300
hCYP11B2 IC50 [nM]
9.4
11.4
th enhanced microsomal stability and retained afﬁnity.
Figure 3. Microﬂuidic device for HLM metabolite analysis.35 Microﬂuidic device for cell culture, metabolite analysis and cytotoxicity assay. (a) The integrated microﬂuidic
device. (b) Microchannels for HLM encapsulation by PEG hydrogels. (c) Design of the on-chip micro-SPE column. (d) Cell culture channel. (e) An image of the microﬂuidic
device ﬁlled with a blue dye in the bioreactor part cell culture part. AP: acetaminophen; APG: acetaminophen-glucuronides. Reproduced by permission of The Royal Society of
Chemistry.
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effectively yield different phase I reactions of drug molecules and
are thus complimentary to both biotransformation and catalytic
reactions. Reactions such as aromatic and benzylic hydroxylation,
dehydrogenation, O-, and N-dealkylation, S-oxidation and less efﬁ-
ciently N-oxidation and O-dealkylation53 as well as reaction with
electrogenerated reactive oxygen species54 have been demon-
strated over the past years.
Different from other technologies, electrochemistry offers a
purely instrument based approach without the need for isolation
of metabolites out of complex biological mixtures and bears the
potential for the rapid generation of larger amounts of metabolites
and diversiﬁed molecules for subsequent testing. Furthermore, the
generation of electrophilic metabolites in absence of biologicalHO
N
H
O
OH
S
Nelfinav
Methylation
Scheme 9. Metabolism of nelﬁnavir prodnucleophiles provides access to unnaturally trapped intermediates
that account for most severe side effects and allows directed mim-
icking of phase II metabolites.55,56
A drawback of electrochemical methods is that the position of
lowest oxidation potential in a molecule does not necessarily mi-
mic the observed sites in in vivo or other in vitro systems thus
complementing the aforementioned technologies. The regioselec-
tivity of a drug molecule oxidation is often more dependent of
the topology of the active sites of the biological systems than of
the effective oxidation energies within the drug molecule.
Although electrochemistry started with experiments in off-line
batch reactors,57 most contemporary systems for electrochemical
metabolite generation feature either ﬂow-based EC-MS or EC-LC–
MS setups.58 Another option is to incorporate the electrochemistryN
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5478 K. P. Cusack et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5471–5483within the electrospray source as the electrospray emitter induces
electro-chemical reactions itself due to its high potential.59
Most current ﬂow-through cells contain a three-electrode set-
up, consisting of reference electrode, counter electrode and work-
ing electrode. These can be amperometric electrodes with
exchangeable electrode materials in a thin layer cell setup or cou-
lometric porous glassy carbon electrodes.60 First microﬂuidic chips
incorporating a thin-layer electrode geometry dedicated to drugN
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based pseudo-reference electrode successfully mimicking the ma-
jor metabolism pathways for procainamide.62 Odijk and Qiao re-
cently published a third generation microchip and demonstrated
the oxidative metabolite formation of mitoxantrone.63 Meanwhile,
Kumacheva et al. reported a method for the fabrication of microﬂu-N
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molding in capillaries and demonstrated the synthetically interest-
ing electrolyte-free anodic methoxylation of 2-pyrrolidinone to
5-methoxy-2-pyrrolidinone in methanol.64
Recent examples in the area of electrochemically generated
metabolites show the increasing options of mimicking speciﬁc
metabolism pathways (Table 3). For example, electrocatalytic oxi-
dation of H2O2 on a platinum electrode generates reactive oxygen
species, presumably surface-bound platinum-oxo species that are
capable of oxygen insertion reactions in analogy to oxo-ferryl rad-
ical cations in the active site of Cytochrome P450 resulting only in
hydroxylation in the 3- and 4-position of Lidocain (Table 3, entry
1).65
Permentier et al. extended the scope of electrochemical meth-
ods with the O-dealkylation of phenacetin to acetaminophen by
square-wave potential pulses (Table 3, entry 6).70 This reaction
could not be achieved by oxidation at constant potential or longer
potential pulses because of the fast hydrolysis of the reactive
intermediates. By performing electrochemical reactions in non-
aqueous systems Tahara et al. could generate and isolate reactive
metabolites of Troglitazone that possibly account for the toxicity
of the parent compound leading to its withdrawal from the market
(Table 3, entry 7) thus proving electrochemical methods to be
useful to prepare and predict reactive metabolites of drugs that
are unstable in aqueous medium or in vivo.71 The same group alsoTable 2
Selected conversions and catalyst systems from recent literature examples47
Entry Reaction class Metal Representative transformation
1
Biomimetic
metalloporphyrin
Mn
Air
OH
2
Biomimetic
metalloporphyrin
Mn
Air
+
OH
OH
Co
Fe
Ni
Cu
Zn
3
Biomimetic
nonmetalloporphyrin
Fe N
PhPh
H2N
O
Ph
H2N
O
PhIO
4
Biomimetic
nonmetalloporphyrin
Fe
H2O2
5
Biomimetic
metalloporphyrin
Fe
N
N
N
N
N
N
HO
Mn
6
C–H Bond
functionalization
Pd N N
F
7
C–H Bond
functionalization
Pd
N
OH
No catalystN
OH
O
Br
NBS
8
C–H Bond
functionalization
Pd
Cl Cl
MesI(OAc)2 ClClreported one of the ﬁrst semi-preparative scale syntheses of an
in vivo metabolite by electrochemical methods for further NMR
analysis.72
At this interface of analytical and preparative electrochemistry
the growing ﬁeld of meso-scale electrochemistry ﬂow-cells73 will
also be of future interest for the generation of larger amounts of
drug metabolites. This will not be limited to oxidative metabolites
but also for late-stage modiﬁcation by for example ﬂuorination and
triﬂuoromethylation reactions at particularly the positions of low-
est oxidation potential. The underlying principle of most meso-
scale cells is a plate-to-plate electrode conﬁguration with distances
in the micrometer order mounted in a non-conducting housing.
Such systems have been employed in the synthesis of p-methoxy-
benzaldehyde dimethyl acetal out of p-methoxytoluene,74 in the
electrolyte-free anodic oxidation of furans in methanol75 and also
for acetoxylation of furan and benzene derivatives.76
Other examples include divided cells for the generation of N-
acyliminium ions out of methyl pyrrolidinecarboxylate and their
subsequent reaction with carbanions generated in a paired micro-
ﬂow system by cathodic reduction.77 This chemistry and also the
regioselective electrochemically-induced cross-coupling reaction
of an aldehyde with allylic chloride were shown in a laminar
ﬂow-controlled microchannel without a membrane between the
two compartments.78 Yoshida et al. also introduced a carbon ﬁber
electrode based microﬂow system in which the electric currentTransformation Refs
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spacer membrane the anodic methoxylation of p-methoxytoluene
was conducted in an electrolyte-free reaction.79 A C–C bond forma-
tion reaction was reported by Haswell et al. in the electro-reduc-
tive coupling of activated oleﬁns and benzyl bromide between
platinum electrodes.80
By adapting strategies from metabolite generation those meso-
scale cells will in the future help to generate preparative amounts
of highly desirable late-stage diversiﬁed drug molecules that are
otherwise tedious to synthesize.
In summary, an integral part of the drug discovery and develop-
ment process involves characterization of the metabolites of a drug
candidate. At the lead optimization stage, metabolite identiﬁcation
can aid drug design efforts on several fronts. The most important
one is the identiﬁcation of metabolically labile positions for com-
pounds with high clearance. In addition, this helps determine
whether any of the pharmacological activity of the drug is due to
active metabolites. This has gained further importance due to the
recent FDA guidance on the importance of characterizing metabo-
lites at a pre-clinical stage.81
The ability to directly access functionalizedmolecules more efﬁ-
ciently than conventional synthetic chemistry techniques is very
attractive to medicinal chemists.82 From a drug discovery perspec-
tive, the ability to introduce hydroxy groups in drug candidates is a
powerful technique to modulate physicochemical properties late in
the lead optimization process. Furthermore, new efﬁcient methods
have emerged, enabling regioselective ﬂuorination of aromatic sub-
strates to improve metabolic stability.37
This perspective has aimed to highlight three complementary
areas that are available to the medicinal chemists, tasked with the
multi-parametric issuesof iterative compounddesignandoptimiza-
tion. Enzymatic transformations represent perhaps the most well-
studied anddevelopedof the three approaches described in this per-
spective. Many fungal and bacteria strains with the capacity for oxi-
dative biotransformation, are useful for the biosynthesis of
otherwise difﬁcult to prepare compounds. As mentioned in the
introduction, much of the knowledge about these microbial tech-
niques comes from screening efforts to identify strains that metab-
olize steroid-like molecules. Evidence indicates that many fungi are
capable of cytochromeP450 super family-like oxidativebiotransfor-
mations. Although cultures of these fungimay provide a convenient
and abundant capacity for enzymatic oxidations, fermentations in a
micro titer plate or a shake ﬂask can be difﬁcult to manipulate in
terms of throughput and isolation. As such, the availability of a
screening kit of BM3 P450 mutants represents a convenient entry
to those interested in investigating the substrate diversity and prod-
uct proﬁle of this class of enzymes. Further, the substrate scope and
selectivity proﬁle attainable with rCYPs, as highlighted by the func-
tionalization of Dasatinib and Fluvastatin represents a powerful
example of this technique. The chemoselectivity and unique ability
for direct C–H activation also expands the scope towards lead diver-
siﬁcation or preparation of non-humanmetabolites, as illustrated in
Scheme 4. Given industry-wide efforts to drive towards compounds
with lower cLogP,83 this avenue will continue to aid drug discovery
scientists. Porphyrin-based catalytic methods offer a powerful ap-
proach to enable selective functionalization of unactivated C–H
bonds in a similar manner to cytochrome P450-based metabolism
pathways. Interest in this ﬁeld is expected to grow, with recent
examples of porphyrin-mediated chlorinations being an attractive
example of the potential expansion in generality and scope. Among
nonporphyrin basedmethods, the development of Fe and Cp⁄Ir pre-
catalysts represent emerging areas for late-stage functionalization
of complex molecules. Important in the utility to practicingmedici-
nal chemists is the easeof experimental setup to screenmultiple cat-
alyst systems, followed by state of the art analytical and separation
tools to enable rapid decisions. Complementary to both these tech-
5482 K. P. Cusack et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5471–5483niques are electrochemistry-based approaches for structural diver-
siﬁcation.While this technique can generatemetabolitesmimicking
speciﬁc metabolism pathways as shown in Table 3, the potential to
‘trap’ reactive metabolites and functionalize them with a range of
nucleophiles, both endogenous and others, offers access to a wide
array of metabolites and diverse structures. In addition, recent ad-
vances in meso-scale electrochemistry enabling the generation of
larger amounts of desired compounds will prove to be quite attrac-
tive for medicinal chemists.
While this perspective is not intended to be a comprehensive
review of the signiﬁcant amount of research that has, and contin-
ues to occur in these three areas, representative examples of the
scope and complementarity of available tools are highlighted. Con-
tinued reﬁnement, in terms of predictability and ease of use, will
be important to drive these techniques into mainstream medicinal
chemistry efforts. Extension of the utility of each of these technol-
ogies beyond simple oxidative transformation is known9,84,85 and
the potential of these tools is enormous. These methods coupled
with predictive tools84a are speeding the production and analysis
of metabolites and enabling earlier proﬁling within the drug dis-
covery funnel. As innovative new transformations are identiﬁed,
the toolbox available to the synthetic chemist will continue to
grow.
Acknowledgments
We would like to thank Robert A.B. van Waterschoot for helpful
comments and discussion in the enzymatic section. K.P.C., H.F.K.,
U.E.W.L., H.M.P., I.P., and A.V. are AbbVie employees. AbbVie partic-
ipated in the review and approval of the manuscript.References and notes
1. Orhan, H.; Vermeulen, N. P. Cur. Drug Metab. 2011, 12, 383.
2. Lohmann, W.; Karst, U. Anal. Bioanal. Chem. 2008, 391, 79.
3. Stepan, A. F.; Mascitti, V.; Beaumont, K.; Kalgutkar, A. S. Med. Chem. Comm.
2013, 4, 631.
4. Marchetti, L.; Levine, M. ACS Catalysis 2011, 1, 1090.
5. Njuguna, N. M.; Masimirembwa, C.; Chibale, K. J. Nat. Prod. 2012, 75, 507.
6. Hogg, J. A. Steroids 1992, 57, 593.
7. Bell, S. R.; Groves, J. T. J. Am. Chem. Soc. 2009, 131, 9640.
8. Narehood, R. A.; Groves, J. T. Metallomics 2011, 3, 775.
9. Lie, W.; Groves, J. T. J. Am. Chem. Soc. 2012, 132, 12847.
10. (a) Kuhl, N.; Hopkinson, N.; Wencel-Delord, J.; Glorius, F. Angew. Chem. Int. Ed.
2012, 51, 10236; (b) Wencel-Delord, J.; Dröge, T.; Liu, F.; Glorius, F. Chem. Soc.
Rev. 2011, 40, 4740.
11. For an overview on CYP mediated phase I metabolism, see: (a) Denisov, I. G.;
Makris, T. M.; Sligar, S. G.; Schichting, S. G. Chem. Rev. 2005, 105, 2253; (b)
Smith, D. A.; van de Waterbeemd, H.; Walker, D. K. Pharmacokinetics and
Metabolism. In Drug Design; Mannhold, R., Kubinyi, H., Timmerman, H., Eds.;
Wiley-VCH, 2001.
12. Modern Biooxidation; Schmid, R. D., Urlacher, V. B., Eds.; Wiley-VCH:Weinheim,
2007.
13. For a recent review on Phase II metabolism, see: Testa, B.; Krämer, S. D. Chem.
Biodiv. 2008, 5, 2171.
14. (a) Venisetty, R. K.; Ciddi, V. Curr. Pharm. Biotechnol. 2003, 4, 153; (b) Moussa,
C.; Houziaux, P.; Danree, B.; Azerad, R. Drug Metab. Dispos. 1997, 25, 311; (c)
Elmarakby, S. A.; Clark, A. M.; Baker, J. K.; Hufford, C. D. J. Pharm. Sci. 1986, 75,
614.
15. (a) Testa, B.; Krämer, S. D. Chem. Biodiv. 2007, 4, 257; (b) Smith, D. A.; Ackland,
M. J.; Jones, B. C. Drug Discov. Today 1997, 2, 479.
16. Arisawa, A.; Agematu, H. Modern Biooxidation In Schmid, R. D., Urlacher, V.,
Eds.; ; Wiley-VCH: Weinheim, 2007; Vol. 1, pp 177–192.
17. For a general review on cofactor regeneration, see: Woodyer, R.D.; Johannes,
T.W.; Zhao, H., 2005, Regeneration of cofactors for enzyme biocatalysis. In
Enzyme Technology (Pandey, A.; Webb, C.; Soccol C.S., Larroche C, eds), pp. 85–
103; Asiatech Publishers Inc., New Delhi, India.
18. (a) Ghisalba, O.; Kittelmann, M. Modern Biooxidation In Schmid, R. D., Urlacher,
V., Eds.; ; Wiley-VCH: Weinheim, 2007; Vol. 1, pp 211–232. Table 1 is
according to experience of Novartis.; Readers are also directed towards recent
advances in human hepatocyte culture technology as demonstrated in (b)
Wang, W. W.; Khetani, S. R.; Krzyzewski, S.; Duignan, D. B.; Obach, S. R. Drug
Metab. Disp. 1900, 2010, 38.
19. Kumar, S. Expert Opin. Drug Metab. Toxicol. 2010, 6, 115.
20. Whitehouse, C. J. C.; Bell, S. G.; Wong, L.-L. Chem. Soc. Rev. 2012, 41, 1218.21. For example, see: Reinen, J.; van Leeuwen, J. S.; Li, Y.; Sun, L.; Grootenhuis, P. D.
J.; Decker, C. J.; Saunders, J.; Vermeulen, N. P. E.; Commandeur, J. N. M. Drug
Metab. Dispos. 2011, 39, 1568.
22. For a screening method of BM-3 P450 variants in a 96-well plate format see:
Schwanenberg, U.; Otey, C.; Cirino, P. C.; Farinos, E.; Arnold, F. H. J. Biomol.
Screen. 2001, 6, 111.
23. Usmani, K. A.; Chen, W. G.; Sadeque, A. J. M. Drug Metab. Dispos. 2012, 40, 761.
24. Li, W.; Josephs, J. L.; Skiles, G. L.; Humphreys, W. G. Drug Metab. Dispos. 2008,
36, 721.
25. Fischer, V.; Johanson, L.; Heitz, F.; Tullmann, R.; Graham, E.; Baldeck, J. P.;
Robinson, W. T. Drug Metab. Dispos. 1999, 27, 410.
26. Ghisalba, O.; Lattmann, R.; Kittelmann, M. Biosci., Biotech., Biochem. 1993, 57,
1589.
27. For example: (a) Codexis, Inc., Redwood City, CA; (b) Metabomics, Inc., China;
(c) Hypha Discovery™ Ltd, Middlesex, UK; (d) HepatoChem, Cambridge, MA;
(e) Evolva; (f) XenoTech.
28. MetaboLyte™ Kit production platform (HepatoChem, Cambridge, MA). See
website at http://www.hepatochem.com/.
29. Hann, M. M. Med. Chem. Commun. 2011, 2, 349.
30. Stepan, A. F.; Mascitti, V.; Beaumont, K.; Kalgutkar, A. S. Med. Chem. Commun.
2013, Advance article, doi: 10.1039/C2MD20317K.
31. Bright, T. V.; Dalton, F.; Elder, V. L.; Murphy, C. D.; O’Connor, N. K.; Sandford, G.
Org. Biomol. Chem. 2013, 11, 1135.
32. (a) T’jollyn, H.; Bousser, K.; Mortishire-Smith, R. J.; Coe, K.; De Boeck, B.; Van
Bocxlaer, J. F.; Mannens, G. Drug Metab. Dispos. 2011, 39, 2066; (b) Jennen, D. G.
J.; Gaj, S.; Giesbertz, P. J.; van Delft, J. H. M.; Evelo, C. T.; Kleinjans, J. C. S. Drug
Discovery Today 2010, 15, 851; (c) Njuguna, N.; Masimirembwa, C.; Chibale, K. J.
Nat. Prod. 2012, 75, 507; (d) Sun, H.; Scott, D. O. Chem. Biol. Drug Res. 2010, 75,
3.
33. Review on Cytochrome P450-activated prodrugs: Ortiz de Montellano, P. R.
Future Med. Chem. 2013, 5, 213.
34. Novik, E.; Maguire, T. J.; Chao, P.; Cheng, K. C.; Yarmush, M. L. Biochem.
Pharmacol. 2010, 79, 1036.
35. Mao, S.; Gao, D.; Liu, W.; Wei, H.; Lin, J.-M. Lab Chip 2012, 12, 219. Reproduced
by permission of The Royal Society of Chemistry. http://dx.doi.org/10.1039/
C1LC20678H.
36. Coelho, P. S.; Brustad, E. M.; Kannan, A.; Arnold, F. H. Science 2013, 339, 307.
37. Furuya, T.; Kamlet, A. S.; Ritter, T. Nature 2011, 473, 470.
38. Zhang, K. E.; Wu, E.; Patrick, A. K.; Kerr, B.; Zorbas, M.; Lankford, A.; Kobayashi,
T.; Maeda, Y.; Shetty, B.; Webber, S. Antimicrob. Agents Chemother. 2001, 45(4),
1086.
39. Chen, M. S.; White, M. C. Science 2007, 318, 783.
40. Zhan, J.; Guo, H.; Dai, J.; Zhang, Y.; Guo, D. Tetrahedron Lett. 2002, 43, 4519.
41. Vermeulen, N. A.; Chen, M. S.; White, M. C. Tetrahedron 2009, 65, 3078.
42. Chen, M. S.; White, M. C. Science 2010, 327, 566.
43. Bigi, M. A.; Liu, P.; Zou, L.; Houk, K. N.; White, M. C. Synlett 2012, 2768.
44. White, M. C. Science 2012, 335, 807.
45. Farooq, A.; Tahara, S. Z. Naturforsch 2000, 55, 341.
46. Ata, A.; Conci, L. J.; Betteridge, J.; Orhan, I.; Sener, B. Chem. Pharm. Bull. 2007, 55,
118.
47. (a) Jiang, G.; Liu, Q.; Guo, C. Biomimetic Oxidation of Hydrocarbons with Air
over Metalloporphyrins, Biomimetic Based Applications, Marko Cavrak (Ed.),
2011.; (b) Bernadou, J.; Meunier, B. Adv. Synth. Catal. 2004, 346, 171; (c)
Nuefeldt, S.; Sanford, M. S. Acc. Chem. Res. 2012, 45(6), 936; (d) Lyakin, O. Y.;
Shteinman, A. A. Kinet. Catal. 2012, 53(6), 738; (e) Balogh, G. T.; Keseru, G. G.
Arkivoc 2004, 7, 124.
48. Bigi, M. A.; Reed, S. A.; White, M. C. J. Am. Chem. Soc. 2012, 134, 9721.
49. Gomez, L.; Canta, M.; Font, D.; Prat, I.; Ribas, X.; Costas, M. J. Org. Chem. 2013,
78, 1421.
50. Zhou, M.; Hintermair, U.; Hashiguchi, B. G.; Parent, A. R.; Hashmi, S. M.;
Elimelech, M.; Periana, R. A.; Brudvig, G. W.; Crabtree, R. H. Organometallics
2013, 32, 957.
51. Dai, H.-X.; Stepan, A. F.; Plummer, M. S.; Zhang, Y.-H.; Yu, J.-Q. J. Am. Chem. Soc.
2011, 133, 7222.
52. For a recent review on C–H transformations using Fe catalysis, see: Sun, C.-L.;
Li, B.-J.; Shi, Z.-J. Chem. Rev. 2011, 111, 1293.
53. For a recent review on electrochemically generated phase-1 and -2 metabolites
see. Álvarez-Lueje, A.; Pérez, M.; Zapata, C. In Topics on Drug Metabolism;
Paxton, J., Ed.; InTech, 2012; pp 221–246.
54. Nouri-Nigjeh, E.; Permentier, H. P.; Bischoff, R.; Bruins, A. P. Anal. Chem. 2010,
82, 7625.
55. Nouri-Nigjeh, E.; Bischoff, R.; Bruins, A. P.; Permentier, H. P. Curr. Drug Metab.
2011, 12, 359.
56. Orhan, H.; Vermeulen, N. Drug Metab. Dispos. 2011, 12, 383.
57. Oshino, N.; Toda, T.; Shono, T. Drug Metab. Dispos. 1981, 481.
58. Karst, U.; Diehl, G. Anal. Bioanal. Chem. 2002, 373, 390.
59. vanBerkel, G. J.; Kertesz, V. Anal. Chem. 2007, 79, 5510.
60. For a recent review please see: Karst, U.; Jahn, S. J. Chromatogr., A 2012, 1259,
16.
61. Odijk, M.; Baumann, A.; Lohmann, W.; van den Brink, F. T. G.; Olthuis, W.;
Karst, U.; van den Berg, A. Lab. Chip 2009, 9, 1687.
62. Odijk, M.; Baumann, A.; Olthuis, W.; van den Berg, A.; Karst, U. Biosens.
Bioelectron. 2010, 26, 1521.
63. Odijk, M.; Olthuis, W.; van den Berg, A.; Qiao, L.; Girault, H. Anal. Chem. 2012,
84, 9176.
64. Simms, R.; Dubinsky, S.; Yudin, A.; Kumacheva, E. Lab. Chip 2009, 9, 2395.
K. P. Cusack et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5471–5483 548365. Nouri-Nigjeh, E.; Bruins, A. P.; Bischoff, R.; Permentier, H. P. Analyst 2012, 137,
4698.
66. Faber, H.; Melles, D.; Brauckmann, C.; Wehe, C. A.; Wentker, K.; Karst, U. Anal.
Bioanal. Chem. 2012, 403, 345.
67. Jahn, S.; Baumann, A.; Roscher, J.; Hense, K.; Zazzeroni, R.; Karst, U. J.
Chromatogr., A 2011, 1218, 9210.
68. Baumann, A.; Faust, A.; Law, M. P.; Kuhlmann, M. T.; Kopka, K.; Schaefers, M.;
Karst, U. Anal. Chem. 2011, 83, 5415.
69. Baumann, A.; Lohmann, W.; Rose, T.; Ahn, K. C.; Hammock, B. D.; Karst, U.;
Schebb, N. H. Drug Metab. Dispos. 2010, 38, 2130.
70. Nouri-Nigjeh, E.; Bischoff, R.; Bruins, A. P.; Permentier, H. P. Analyst 2011, 136,
5064.
71. Tahara, K.; Nishikawa, T.; Hattori, Y.; Iijima, S.; Kouno, Y.; Abe, Y. J. Pharm.
Biomed. Anal. 2009, 50, 1036.
72. Tahara, K.; Yano, Y.; Kanagawa, K.; Abe, Y.; Yamada, J.; Iijima, S.; Mochizuki, M.;
Nishikawa, T. Chem. Pharm. Bull. 2007, 55, 1207.
73. Yoshida, J.-I. Electrochem. Soc. Interface 2009, 18, 40.
74. Ziogas, A.; Kolb, G.; O’Connell, M.; Attour, A.; Lapicque, F.; Matlosz, M.; Rode, S.
J. Appl. Electrochem. 2009, 39, 2297.
75. Watts, K.; Gattrell, W.; Wirth, T. Beilstein J. Org. Chem. 2011, 7, 1108.
76. Horii, D.; Atobe, M.; Fuchigami, T.; Marken, F. J. Electrochem. Soc. 2006, 153,
143.77. (a) Suga, S.; Okajima, M.; Fujiwara, K.; Yoshida, J.-I. J. Am. Chem. Soc. 2001, 123,
7941; (b) Suga, S.; Okajima, M.; Fujiwara, K.; Yoshida, J.-I. QSAR Comb. Sci. 2005,
24, 728.
78. (a) Horii, D.; Fuchigami, T.; Atobe, M. J. Am. Chem. Soc. 2007, 129, 11692; (b)
Amemiya, F.; Matsumoto, H.; Fuse, K.; Kashiwagi, T.; Kuroda, C.; Fuchigami, T.;
Atobe, M. Org. Biomol. Chem. 2011, 9, 4256.
79. Horcajada, R.; Okajima, M.; Suga, S.; Yoshida, J.-I. Chem. Commun. 2005, 1303.
80. He, P.; Watts, P.; Marken, F.; Haswell, S. J. Angew. Chem., Int. Ed. 2006, 45, 4146.
81. Food and Drug Administration. Guidance for Industry: Safety Testing of Drug
Metabolites. FDA, Rockville, MD. 2008.
82. Bryan, M. C.; Dillon, B.; Hamann, L. G.; Hughes, G. J.; Kopach, M. E.; Peterson, E.
A.; Pourashraf, M.; Raheem, I.; Richardson, P.; Richter, D.; Sneddon, H. F. J. Med.
Chem. 2013, article ASAP. doi: 10.1021/jm400250p.
83. Leeson, P. D.; Springthorpe, B. Nat. Rev. Drug Disc. 2007, 6, 881.
84. (a) Masood, M. A.; Farrant, E.; Morao, I.; Bazin, M.; Perez, M.; Bunnage, M. E.;
Fancy, S.-A.; Peakman, T. Biorg. Med. Chem. Lett. 2012, 22, 723; (b) Masood, M.
A.; Bazin, M.; Bunnage, M. E.; Calabrese, A.; Cox, M.; Fancy, S.-A.; Farrant, E.;
Pearce, D. W.; Perez, M.; Hitzel, L.; Peakman, T. Biorg. Med. Chem. Lett. 2012, 22,
1255.
85. Lu, H.; Zhang, X. P. Chem. Soc. Rev. 2011, 40, 1899.
